Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evobrutinib vs Avonex in Relapsing Multiple Sclerosis
NCT04032158Phase 3Terminated
- Sponsor
- EMD Serono
- Start
- Aug 2019
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of evobrutinib in multiple sclerosis (MS) (2 arms), sponsored by EMD Serono. Primary endpoint: Annualized Relapse Rate at 96 weeks. Started Aug 2019; status: terminated.
02
Drugs
evobrutinib
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT04032158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04032158.